Optimal antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI) should consist of both oral anticoagulation (OAC) and antiplatelet therapy to effectively prevent major adverse cerebral (stroke) and cardiac (death, myocardial infarction, urgent revascularization, and stent thrombosis) ischemic events (MACCE). While the so-called triple therapy with a vitamin K-antagonist (VKA), aspirin and clopidogrel has long been proposed as the default strategy [1], double therapy with a non-vitamin K-antagonist (NOAC) and clopidogrel has subsequently shown a more favorable net clinical effect, being associated with less bleeding events and no apparent increase in MACCE [2,3].
